HomeCompareNNBXF vs BTI

NNBXF vs BTI: Dividend Comparison 2026

NNBXF yields 21.98% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNBXF wins by $44.7K in total portfolio value
10 years
NNBXF
NNBXF
● Live price
21.98%
Share price
$9.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.4K
Annual income
$8,278.86
Full NNBXF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — NNBXF vs BTI

📍 NNBXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNNBXFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NNBXF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NNBXF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNBXF
Annual income on $10K today (after 15% tax)
$1,868.13/yr
After 10yr DRIP, annual income (after tax)
$7,037.03/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, NNBXF beats the other by $4,668.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNBXF + BTI for your $10,000?

NNBXF: 50%BTI: 50%
100% BTI50/50100% NNBXF
Portfolio after 10yr
$60.0K
Annual income
$5,532.75/yr
Blended yield
9.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

NNBXF
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNBXF buys
0
BTI buys
0
No recent congressional trades found for NNBXF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNNBXFBTI
Forward yield21.98%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$82.4K$37.7K
Annual income after 10y$8,278.86$2,786.64
Total dividends collected$49.1K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NNBXF vs BTI ($10,000, DRIP)

YearNNBXF PortfolioNNBXF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$12,898$2,197.80$11,299$598.92+$1.6KNNBXF
2$16,450$2,649.24$12,794$703.91+$3.7KNNBXF
3$20,759$3,157.79$14,518$829.07+$6.2KNNBXF
4$25,937$3,724.32$16,513$978.64+$9.4KNNBXF
5$32,101$4,348.78$18,827$1,157.84+$13.3KNNBXF
6$39,378$5,030.23$21,518$1,373.12+$17.9KNNBXF
7$47,902$5,766.90$24,657$1,632.46+$23.2KNNBXF
8$57,811$6,556.21$28,329$1,945.74+$29.5KNNBXF
9$69,253$7,394.84$32,637$2,325.33+$36.6KNNBXF
10$82,379$8,278.86$37,708$2,786.64+$44.7KNNBXF

NNBXF vs BTI: Complete Analysis 2026

NNBXFStock

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Full NNBXF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this NNBXF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNBXF vs SCHDNNBXF vs JEPINNBXF vs ONNBXF vs KONNBXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.